SPONSORSHIP AGREEMENT

This Sponsorship Agreement ("**Agreement**") is entered into as of September 17, 2024 ("**Effective Date**") by and between Novartis Healthcare A/S, Reg. No. 20575786, a company incorporated under the laws of Denmark, located at Edvard Thomsens Vej 14, DK-2300 Copenhagen S, Denmark ("**Novartis**") and LyLe Patientforening for Lymfekræft, Leukæmi og MDS, an Organization incorporated under the laws of Denmark, located at Banetoften 26, 4700 Næstved, ("**Sponsership Recipient**"). Novartis and Sponsorship Recipient may hereinafter be referred to individually as a "**Party**" and collectively as the "**Parties**".

WHEREAS, Sponsorship Recipient has specifically requested Novartis' financial contribution in order to support the Sponsorship Activity (as defined in Exhibit A), through a Sponsorship Request Letter, which is attached hereto as Exhibit B;

WHEREAS, in accordance with the Sponsorship Request Letter mentioned above, Novartis wishes to support the Sponsorship Activity with the Sponsorship Amount (as defined in Exhibit A);

WHEREASS, Novartis will receive a tangible benefit in connection with the sponsorship (as defined in Exhibit A); and

WHEREAS, Sponsorship Recipient accepts the Sponsorship Amount subject to the terms and conditions of this Agreement.

NOW THEREFORE, in consideration of the premises and the mutual covenants herein contained, it is mutually agreed as follows:

1. SPONSORSHIP BY NOVARTIS

1.1 **Sponsorship**. Novartis will provide the Sponsorship Amount as set forth in Exhibit A solely to support Sponsorship Recipient in performing the Sponsorship Activity as set forth in Exhibit A.

1.2 **Tangible benefit**. Novartis will receive a tangible benefit as set forth in Exhibit A.

1.3 **Statement of Purpose**. The Sponsorship Activity is for: produktion af hvidbog om de hæmatologiske sygdomme i forbindelse med Kræftplan V.

1.4 **Novartis Responsibility**. Sponsorship Recipient agrees that Novartis' responsibility is solely to provide the Sponsorship Amount and to receive the tangible benefit. Novartis will not be liable to Sponsorship Recipient or to any other person for the Sponsorship Activity or the use of the Sponsorship Amount (including any claims or losses related thereto). Novartis may terminate this Agreement and require Sponsorship Recipient to return the Sponsorship Amount and take other corrective action if Sponsorship Recipient breaches this Agreement.

2. OBLIGATIONS OF SPONSORSHIP RECIPIENT

2.1 **Use of Sponsorship Amount**.

(a) Sponsorship Recipient shall use the Sponsorship Amount solely for the Sponsorship Activity and shall not use the Sponsorship Amount for any activity that is inconsistent with, or prohibited by any

law, rule or regulation. The Sponsorship Recipient undertakes to independently contact Novartis in the event any part of the Sponsorship Amount has not been used for the Sponsorship Activity so that such amount can be refunded to Novartis without undue delay.

(b) Sponsorship Recipient will comply with (and shall be solely responsible for any failure to comply with) all relevant laws, rules and regulations (including any code of practice or other guidelines generally followed by pharmaceutical companies in the relevant country) in connection with the Sponsorship Activity. Sponsorship Recipient warrants that the Sponsorship Activity is compliant with all such requirements.

(c) Sponsorship Recipient is solely responsible for the manner in which the Sponsorship Amount is disbursed, recorded and accounted and for all contractual and other relationships with third parties relating to the Sponsorship Activity and the use of the Sponsorship Amount. Any claims for payment from third parties involved in the Sponsorship Activity are the sole responsibility of Sponsorship Recipient and Novartis will not fund any additional amounts for the Sponsorship Activity.

2.2 **Objectivity & Balance**.

(a) The Sponsorship Activity will be independent, non-promotional and free from commercial influence or bias.

(b) If the Sponsorship Activity involves the discussion of Novartis products, or the comparison of Novartis products with other products, that discussion and/or comparison must be objective, balanced, accurate, not misleading or deceptive and in compliance with all applicable laws, rules and regulations. Where appropriate, the Sponsorship Activity will include a discussion of multiple treatment options, and will not focus on a single product.

(c) Sponsorship Recipient will ensure that any titles or overview information relating to the Sponsorship Activity will fairly and accurately represent the scope of the planned activity.

(d) If required, Sponsorship Recipient is responsible for selection of presenters, moderators and collaborators for the Sponsorship Activity. Novartis will not control the planning, content, speaker selection or execution of any Sponsorship Activity. If Novartis suggests presenters, moderators or collaborators, Sponsorship Recipient will record the role of Novartis in making the suggestion, seek other sources and make a final selection based on balance and independence.

2.3 **Disclosure of Financial Relationships**.

(a) Sponsorship Recipient will: (i) disclose, to all audiences and in all publications relating to the Sponsorship Activity, that Novartis has provided a Sponsorship to support the Sponsorship Activity; (ii) acknowledge support from Novartis in brochures, syllabi, and other materials related to the Sponsorship Activity; and (iii) disclose any other relationships Novartis has with any individual speakers, moderators, collaborators or Sponsorship Recipient which a reasonable and ethical person would expect to be disclosed.

(b) Novartis may disclose publicly the financial and non-financial support provided to Sponsorship Recipient, including, without limitation, the Sponsorship Recipient's identity, the Sponsorship Amount and purpose of the support.

2.4 **Ancillary Activities**.

(a) If the Sponsorship Activity occurs as part of an overall activity that includes commercial activities, such activities will neither influence planning nor interfere with the Sponsorship Activity. No commercial activities will be permitted in the same room as an educational activity, unless (i) this is allowed in the country in which the activity will take place and (ii) only to the extent that such commercial activity does not interfere with the purpose of the Sponsorship Activity.

(b) The scheduling of meals and/or receptions, if any, in connection with any portion of the Sponsorship Activity is at the sole discretion of Sponsorship Recipient. Meals and/or receptions, if any, will be modest and conducive to the Sponsorship Activity, and the amount of time at the meals or receptions will be clearly subordinate to the overall amount of time.

(c) Reconciliation of Expenses. At the conclusion of the Sponsorship Activity, Sponsorship Recipient will provide to Novartis a reconciliation of the actual expenses versus estimated expenses and will issue a refund to Novartis for any portion of the Sponsorship Amount not incurred in the implementation of the Sponsorship Activity. In addition, Sponsorship Recipient will retain appropriate records of the Sponsorship Activity and the use of the Sponsorship Amount and will provide evidences (as further specified in Exhibit A) to Novartis to document that the Sponsorship Amount has been used in accordance with this Agreement.

3. GENERAL

3.1 **Entire Agreement**. This Agreement, together with its Exhibits, sets forth the entire agreement and understanding of the Parties as to the subject matter hereof and supersedes all proposals, oral or written, and all other prior communications between the Parties with respect to such subject matter. In the event of any conflict between a substantive provision of this Agreement and any Exhibit hereto, the substantive provisions of this Agreement shall prevail.

3.2 **Governing Law and Jurisdiction**. This Agreement shall be governed by and construed under the laws of Denmark, without giving effect to the conflicts of laws provision thereof. Any dispute or claim arising out of or in connection with this Agreement which cannot be settled amicably between the Parties, is to be brought before the Maritime and Commercial Court in Copenhagen or, if this court is not competent, before a competent court of law in the Kingdom of Denmark.

3.3 **Counterparts**. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the Parties intending to be bound have caused this Agreement to be executed by their duly authorized representatives.

NOVARTIS HEALTHCARE A/S

Date and Signature 1 –Contract Owner

By: _____

Name: Susanne Strauss

Date and Signature: DocuSigned by: Susanne Strauss E8437D17EF104C7... 19-Sep-2024 | 7:34:14 AM GMT

Title: Healthcare Manager

LyLe

By: _____

Name: Rita O. Christensen

Title: Formand

Date and Signature: DocuSigned by: Rita O. Christensen F92DBD4EBA834E6... 19-sep-2024 | 8:04:49 AM EDT

Date and Signature 2 –Business Approver

By: _____

Name: Mille Holst

Title: Marketing Director

Date and Signature: DocuSigned by: Mille Holst 1C86847BE9484D4... 19-Sep-2024 | 10:18:20 AM GMT

EXHIBIT A

SPONSORSHIP AMOUNT & SPONSORSHIP ACTIVITY

Sponsorship Amount: ***50.000*** DKK

3.4 Sponsorship Activity: grafisk arbejde og trykning af hvidbog om de hæmatologiske sygdomme i forbindelse med Kræftplan V.

_____

_____

_____

Tangible Benefit: Novartis' navn bliver bragt i Hvidbogen.

_____

_____

_____

Evidences must be provided to Novartis upon completion of the Sponsorship Activity:

The Sponsorship amount is payable against the corresponding invoice within sixty (30) days of its receipt and at the end of a calendar month.

The invoice shall include all details (including a Purchase Order Number) as specified in the Purchase Order received by Sponsorship Recipient at the following email address: invoice.denmark@novartis.com

When effectuating the payment Novartis will include the following reference: LyLe Hvidbog

EXHIBIT B

SPONSORSHIP REQUEST LETTER

Ansøgning om yderligere støtte til produktion af en hvidbog om de hæmatologiske sygdomme i forbindelse med Kræftplan V

Manus til hvidbogen foreligger nu og tilbage står produktionen af bogen og vores møder med udvalgte medlemmer af Sundhedsudvalget på Christiansborg. Vi sender hermed oplægget vedhæftet til gennemlæsning.

Vi mangler på nuværende tidspunkt stadig det grafiske arbejde og trykning af bogen samt planlagte PA-indsats. Se budgetoversigt herunder.

Formålet med ansøgningen er som følger:

Behandlingen af blodkræftsygdomme taber terræn i Danmark

I LyLe har vi noteret os regeringens initiativer til at skabe forbedringer på kræftområdet, og vi har et stærkt ønske om – gennem udarbejdelsen af en hvidbog for hæmatologien – at bidrage til og sætte vores specifikke aftryk i Kræftplan V, der forventes lanceret i efteråret 2024.
Kræftplan V har som sit hovedfokus at genskabe tilliden til kræftbehandlingen og sikre en fortsat videreudvikling og fremtidssikring af kræftområdet. Kernetemaer er her forebyggelsen af kræft, at sikre at flere overlever kræft gennem anvendelse af nye, effektive og målrettede lægemidler, og at flest muligt får et godt liv som raske eller kroniske kræftpatienter.

Vi anbefaler derfor, at Kræftplan V har fokus på hele patientens forløb og ønsker at sætter fokus på tre kerneområder for hæmatologien, som ikke er tilstrækkeligt implementeret efter Kræftplan IV :

Det er:
1. Tidlig diagnose
2. Opdateret behandling
3. Mere fokus på senfølger

1. Diagnose: Tidlig diagnose er et vigtigt tema for hæmatologiske patienter. Ligesom med andre kræftsygdomme er tidlig diagnose vigtig for patientens sygdoms- og behandlingsforløb og for muligheden for at overleve sygdommen med en god livskvalitet. I processen frem mod en præcis diagnose er blodkræftpatienter ofte udfordret af, at symptomerne på fx akut leukæmi eller lymfekræft er diffuse og kan forveksles med symptomer på mere almindelige infektionssygdomme.

Imidlertid dækker blodkræft over en lang række relativt sjældne sygdomme, som en praktiserende læge vil møde meget sjældent. Derfor kan vejen fra tidlige symptomer til en præcis diagnose og adækvat behandling være meget lang med risiko for sygdomsforværring, livstruende

komplikationer og unødvendig, tidlig død. Af den grund er der behov for at udvikle værktøjer til et generelt vidensløft i behandlingssystemet og blandt en række særlige målgrupper.

2. Behandling: Behandlingen af de hæmatologiske sygdomme har oplevet betydelige fremskridt de senere årtier. Sandsynligheden for at overleve blodkræft er blevet mærkbart forbedret, ikke mindst fordi behandlingen er blevet mere målrettet og personligt tilpasset. I en række af de mest almindelige sygdomme er kemoterapi på tilbagetog. Med avancerede, nye lægemidler er det blevet muligt ikke kun at forbedre overlevelsen, men også at begrænse skaderne af ofte meget bivirkningstunge ældre behandlinger. Desværre oplever vi i Danmark, at det etablerede godkendelses- og ibrugtagningssystem for nye lægemidler er trægt, og det ses stadigt hyppigere, at behandlinger, der er etableret i landene omkring os, ikke er tilgængelige her i landet. I Lyle har vi eksempler på patienter, der har opsøgt fx CAR-T-cellebehandling i Tyskland for egen regning, fordi det ikke er muligt at få denne behandling herhjemme.

Danmark taber med andre ord terræn, når det gælder kræftoverlevelse, men også som kvalificerede partnere i forsøgs- og forskningssammenhæng. Dertil kommer at uligheden i behandlingen er et tiltagende problem. Ressourcestærke og indsigtsfulde patienter har generelt langt bedre forudsætninger for at få den optimale behandling og dermed komme bedre gennem deres behandlings- og sygdomsforløb.

3. Senfølger: I Danmark er der knapt 400.000, der har eller har haft kræft, og af dem oplever mere end halvdelen at være ramt af senfølger. Der er en direkte sammenhæng mellem omfanget og alvoren af senfølger af kræftbehandling og adgangen til nye og mere effektive lægemidler. Samfundsøkonomisk taler meget for, at det, der kan spares på ikke at tage nye, dyre lægemidler i brug, går tabt, når regningen for behandling af senfølger skal betales.

Når det gælder de hæmatologiske sygdomme, skyldes senfølgerne i meget høj grad højdosis kemoterapier, og den helt store udfordring for patienterne er, at de ikke ved, hvad de selv kan gøre for at lindre de ofte meget ubehagelige gener, eller hvor de kan få hjælp.

Senfølger betragtes af det danske sundhedssystem som selvstændige sygdomme og bliver ikke set i den sammenhæng, de er opstået i. Derfor er behandlingen af senfølger spredt fægtning. I hæmatologien har vi dygtige læger, men de ved ikke nok om, hvad de skal stille op med senfølger. Hvis vi for alvor skal gøre noget ved det, skal der tænkes mere holistisk, og det kan vores sundhedssystem ikke håndtere på nuværende tidspunkt. Derfor er det nødvendigt, at Kræftplan V får et specifikt fokus på senfølger.

Budgetoverslag:

Indledende arbejde og research	30.000,- DKK
Tekstproduktion	75.000,- DKK
Grafisk tilrettelægning	40.000,- DKK

Produktionsstyring og tryk (2-300 stk)	30.000,- DKK
Formidlingsindsats og medierettet kommunikationsindsats	35.000,- DKK
PA Indsats*: (anslået)	50.000,- DKK
I alt:	**260.000,- DKK eks. moms**

***PA indsatsen omfatter i korthed:**

Research på sagen og kortlægning af relevante 'targets'
Opsætning af personlige møder mellem relevante politikere og LyLe.
Opfølgning
Løbende møder mellem LyLe, Eyelevel og Reimars Bureau
Oversigt over resultater, modtagelse og erfaringer til det videre forløb.

Sponsoraftaler:
Alle sponsorers navne bringes i Hvidbogen aht. transferens og tilkendegivelse af støtten til bogen.

Fakta:

2.600 danskere får hvert år enten lymfekræft, leukæmi eller MDS, og tallet er stigende. I dag lever godt 20.000 danskere med hæmatologisk kræft, også kaldet blodkræft. Mange døjer med livsødelæggende senfølger af behandlinger, der hører fortiden til.
LyLe er en selvstændig, patientnær patientforening for mennesker med lymfekræft, leukæmi og myelodysplastisk syndrom (MDS). Foreningen blev stiftet i 2007 og er landsdækkende med en aktiv rådgivningsvirksomhed, en lang række lokale netværksgrupper og en vidtfavnende kommunikations-virksomhed på både digitale og fysiske platforme. Foreningen har ca. 1.100 medlemmer, men et betydelig større antal søger viden på LyLes indholdsrige og frit tilgængelige hjemmeside og læser foreningens nyhedsbreve og bladudgivelser. LyLe arbejder målrettet på at være opdateret på de hæmatologiske sygdomme og deres behandling ligesom vi gennem vores internationale patient-samarbejde nøje følger udviklingen i vores nabolande og hele Europa.

Mange hilsner fra

Rita O. Christensen

Rita O. Christensen